ERT Announced Partnership with Cogstate to Expand its eCOA Solution for Higher Fidelity CNS Assessments
ERT, the global leader in clinical endpoint data collection, today announced a preferred partnership with Cogstate to expand its industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoints from Cogstate to support the development […]
Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Memory Impairment
Cogstate today announced an award from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) initiative, which is a partnership of funders seeking to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias. The up to $1.3 million award to Cogstate will be focused on the development of a technology-based approach for early detection of memory impairment and decline.
Eisai Co., Ltd (Tokyo) today announced the launch of “NouKNOW”, a digital tool for self-assessment of brain health based upon technology created by Cogstate. The Japanese product launch will occur on 31 March 2020 and will initially target municipalities providing health services to local residents and corporations providing health checks for employees.
Cogstate announced today that Ken Billard has joined the company in the role of Chief Commercial Officer. Ken brings proven expertise in sales leadership and strategic partnering to Cogstate, where he will oversee the global sales organization to develop and execute strategies focused on expanding the adoption of Cogstate solutions in pharmaceutical clinical trials.
Cogstate today announced a presentation entitled, “Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research Approach” will be delivered at the National Organization for Rare Diseases (NORD) Rare Disease Summit in Washington, D.C.
Cogstate, today announced that its Healthcare Division has received CE Mark approval for its Cognigram™ digital cognitive assessment system.
A new research framework for understanding Alzheimer’s disease has been developed and released by the Alzheimer’s Association (AA) and the National Institute on Aging (NIA).
Cogstate today announced the establishment of a Rare Disease and Pediatric Center of Excellence to lead all activities related to the selection and administration of cognitive and behavioral outcome measures in rare disease and pediatric clinical trials.
Cogstate today announced the appointment of Eric Siemers, M.D., as Distinguished Medical Adviser. Dr. Siemers will provide expert advice for Cogstate’s pharmaceutical customers with regard to the design of clinical trials of neurodegenerative diseases.
International publications validate Cogstate technology’s clinical value in detecting Postoperative Cognitive Dysfunction (POCD)
From the Interdisciplinary Conference on Orthopedic Value Based Care sponsored by the American College of Perioperative Medicine, Cogstate announced that the Cogstate Brief Battery™ has now been shown to be useful for guiding decision making about cognitive outcomes in older adults awaiting or undergoing surgery.
Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar
Cogstate today announced the addition of Dr. Chris Edgar, Senior Vice President, Clinical Science to its global scientific leadership team. Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy.
Global Alzheimer’s Platform Foundation Selects Cogstate for Industry-First Rater Certification Program
Cogstate today announced it has been chosen by the Global Alzheimer’s Platform (GAP) Foundation to support GAP’s rater certification program (RCP) that will significantly increase the speed and quality of Alzheimer’s clinical trials.